Exelixis | EXEL - أصول متداولة





أصول متداولة تغيير تاريخ
Acadia Pharmaceuticals USD 1.27B 43.88M 2026-09
Agios Pharmaceuticals USD 752.1M 34.43M 2026-09
Akebia Therapeutics USD 220.78M 8.77M 2026-09
Amgen USD 34.36B 598M 2026-09
AstraZeneca USD 31.45B 3.48B 2026-09
Bayer EUR 39.6B 5.96B 2026-09
BioMarin Pharmaceutical USD 3.92B 50.99M 2026-09
Bristol-Myers Squibb USD 29.77B 1.19B 2026-09
Cytokinetics USD 1.19B 21.34M 2026-09
Eisai JPY 866.82B 16.2B 2026-09
Eli Lilly USD 65.26B 591M 2026-09
Exelixis USD 1.32B 70.8M 2026-09
Genmab DKK 2.8B 228M 2026-06
Glaxosmithkline GBP 17.9B 134M 2026-09
Incyte USD 5.52B 505.2M 2026-09
Ionis Pharmaceuticals USD 2.36B 129.77M 2026-09
MacroGenics USD 295.08M 26.61M 2026-09
Merck USD 38.94B 2.26B 2026-09
Moderna USD 7.34B 1.53B 2026-09
Nektar Therapeutics USD 589.04M 322.77M 2026-03
Neurocrine Biosciences USD 2.01B 370.7M 2026-09
Novartis USD 28.75B 1.4B 2026-09
Pfizer USD 45.01B 3.65B 2026-09
Puma Biotechnology USD 143.58M 7M 2025-09
Sanofi EUR 31.52B 1.36B 2026-06
Takeda JPY 3T 153.11B 2026-09
Ultragenyx Pharmaceutical USD 544M 62M 2026-09
Xencor USD 498.66M 24.55M 2026-09